Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
NCT00461045
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
15
Enrollment
INDUSTRY
Sponsor class
Conditions
Multiple Myeloma
Interventions
DRUG:
MRZ 0.5 mg/m^2
Sponsor
Celgene